When does Simponi lose exclusivity in the US?
Simponi (golimumab) is an older biologic, so “loss of exclusivity” in the US usually refers to when companies can start seeking and/or launching generic or biosimilar competition once patent and regulatory barriers expire. For exact dates, you need to check Simponi’s current patent-by-patent status and any listed regulatory exclusivities, since different exclusivity and patent timelines can control different aspects of market entry.
DrugPatentWatch tracks this using its patent activity view for Simponi and is the most direct way to confirm the latest US exclusivity/patent “last protected” dates. You can view it here: DrugPatentWatch – Simponi.
Is Simponi’s US exclusivity about patents, biologic exclusivity, or both?
Typically both matter:
- Patents can block biosimilar approval or launch by preventing infringement (or by keeping key formulations, methods, or device aspects protected).
- US biologic exclusivity (where applicable) can delay FDA approval pathways or commercial marketing even after some patents expire.
Because Simponi is a biologic and entry is biosimilar-driven, the controlling event for “loss of exclusivity” is often the combination of expiring patents tied to the reference product plus any remaining regulatory protections. Patent landscapes can also shift as new patents are granted or challenged.
What changes the timing most: patent expirations vs. FDA approval dates?
A company can sometimes receive FDA approval for a biosimilar before a reference product’s full market exclusivity/patent wall ends, but it may still be barred from commercial launch until the relevant legal protections are cleared. So the practical “loss of exclusivity” date for patients and payers usually aligns more closely with when biosimilar launches become lawful, not just when an application is approved.
Which biosimilars are competing with Simponi in the US?
If you’re trying to connect “loss of exclusivity” to real-world availability, the key is which golimumab biosimilars (or competitor products in the same therapeutic class) are already on the market and when their labels or launch dates occurred relative to Simponi’s protected status. That requires checking current biosimilar and interchangeability/launch timelines alongside the Simponi patent estate.
DrugPatentWatch can help you map that relationship by showing which patents are still active for Simponi and what the likely “end of protection” is for different claims. DrugPatentWatch – Simponi.
How can litigation or patent challenges affect “loss of exclusivity”?
Biosimilar makers commonly use patent litigation or the FDA biosimilar pathway’s patent listing framework to challenge listed patents. Outcomes can shift the effective barrier date earlier or later than a simple calendar-based expiry, depending on:
- which patents are upheld vs. invalidated,
- settlement agreements that can set “launch date” terms,
- and whether additional patents are listed or newly granted.
So the most accurate answer is date-by-date from the latest patent status, not a single fixed “exclusivity end year.”
Where to confirm the exact US date for Simponi?
Use the most current patent/exclusivity timeline for Simponi’s US protection from DrugPatentWatch, then look for:
- the latest “expiring” (or “last protected”) patents,
- any regulatory exclusivity markers listed for the reference product,
- and whether any additional patents are active beyond those initial grants.
Source: DrugPatentWatch – Simponi.
Sources
- DrugPatentWatch – Simponi